WHO expands the list of essential medicines and proposes a new working group to address ways to make highly priced essential medicines more affordable and accessible.

On October 1, 2021, the WHO published the new edition of its Model Lists (the EML) of Essential Medicines and Essential Medicines for Children. WHO Documents Press Release Executive Summary World Health Organization model list of essential medicines: 22nd list… Continue Reading

KEI Submission to WHO Essential Medicines List – Enzalutamide / Abiraterone Acetate

The WHO Essential Medicines List is a major WHO tool used to expand access to medicines.  In 2017, the WHO issued the 20th Essential Medicines List (EML) which was the 40th anniversary of the list.  The WHO is currently in… Continue Reading

January 2013: Proposal for the inclusion of trastuzumab in WHO EML for treatment of HER2-Positive Breast Cancer

On 14 January 2013, Knowledge Ecology International (KEI), the University of California (San Francisco), Universities Allied for Essential Medicines (UAEM), Third World Network (TWN) and Young Professionals Chronic Disease Network: YP-CDN submitted a Proposal for the Inclusion of Trastuzumab in the WHO Model List of Essential Medicines for the Treatment of HER2-Positive Breast Cancer to WHO’s Exper Continue Reading

Call for Action on Cancer Drugs by YP-CDN, KEI, and UAEM at 67th World Health Assembly

At the opening of the 67th World Health Assembly, today the Young Professionals Chronic Disease Network (YP-CDN), Knowledge Ecology International (KEI), and Universities Allied for Essential Medicines (UAEM) released a briefing, “Cancer medicines are essential in reducing the global burden of non-communicable diseases.”

Continue Reading

Approval, ownership, market structure, and placement on WHO EML for 100 new cancer NMEs on NCI alpha list

KEI research associate Paul Miano has written the following paper: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines. KEI Research Note 2011:1,

A full copy of the paper is available in PDF format here.

The following is from the introduction (sans footnotes, which are in the PDF version):

Introduction and Summary

Continue Reading